HCWB HCW Biologics Inc.
Price Chart
Executive Summary
Nasdaq Hearings Panel granted HCW Biologics an extension until July 29, 2026 to regain compliance with the $1 minimum bid price rule, following a hearing on May 5, 2026. The company must demonstrate a bid price at or above $1 for 20 consecutive trading days by the deadline, or face immediate delisting. The company was not eligible for the standard 180-day cure period due to a prior reverse stock split.
Actionable Insight
The stock faces a binary outcome by July 29, 2026: either the bid price recovers above $1 for 20 consecutive days, or Nasdaq delists the stock. Delisting would severely reduce liquidity and institutional ownership. Monitor daily bid price and any capital-raising or reverse-split announcements. The recent insider buying suggests some confidence, but the prior reverse split failure is a strong negative signal.
Key Facts
- Nasdaq Hearings Panel granted an extension to July 29, 2026 to regain compliance with the $1 minimum bid price rule.
- Company must exhibit a bid price at or above $1 for 20 consecutive trading days by July 29, 2026.
- If the company becomes deficient with the Bid Price Rule before September 22, 2026, it will be immediately delisted.
- Company was not afforded the standard 180-day cure period because it had already effected a 1-for-40 reverse stock split on April 11, 2025.
- If compliance is regained, the Panel intends to impose a Discretionary Panel Monitor for an additional one-year period.
- Market cap is approximately $13 million, and recent insider buying totaled $430,000 over 30 days.
Financial Impact
No financial figures provided in the filing. The $13M market cap and $430K insider buying are from market data snapshot, not the filing.
Risk Factors
- Failure to meet the July 29, 2026 deadline would result in immediate delisting from Nasdaq.
- Any deficiency in the Bid Price Rule before September 22, 2026 triggers immediate delisting without further cure.
- Non-compliance with any other listing rule before September 22, 2026 could also lead to delisting.
- The company has already exhausted a reverse stock split to address the bid price issue, limiting available remedies.
- Delisting would likely cause a sharp decline in stock price and trading volume.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026529 |
| Document: 0001493152-26-026529-index-headers.html | 0001493152-26-026529 |
| Document: 0001493152-26-026529-index.html | 0001493152-26-026529 |
| Document: 0001493152-26-026529.txt | 0001493152-26-026529 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
4d ago
|
8-K
| $2.07 $1.79 | ▲ +13.53% | ▲ +13.67% | $1.63 (+21.50%) |
|
May 27, 2026
8d ago
|
Insider Cluster
| $2.09 $1.98 | ▼ −5.26% | ▼ −5.50% | $1.63 (−22.25%) |
|
May 27, 2026
9d ago
|
8-K
| $1.94 $2.09 | ▲ +7.73% | ▲ +7.18% | $1.63 (−16.24%) |
|
May 21, 2026
14d ago
|
8-K
| $2.89 $2.62 | ▲ +9.34% | ▲ +9.93% | $1.63 (+43.77%) |
|
May 21, 2026
15d ago
|
Press Release
| $2.58 $2.89 | ▼ −12.02% | ▼ −11.57% | $1.63 (+37.02%) |
|
May 14, 2026
21d ago
|
8-K
| — | awaiting T+1 | — | — |
|
May 14, 2026
21d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
May 14, 2026
22d ago
|
Press Release
| $0.3370 $1.22 | ▲ +262.02% | ▲ +263.24% | $1.63 (+382.20%) |
|
Apr 30, 2026
5w ago
|
8-K
| — | awaiting T+1 | — | — |
|
Apr 24, 2026
5w ago
|
S-1/A
| $0.4390 $0.4000 | ▼ −8.88% | ▼ −8.40% | $1.63 (+270.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access